Related Experiment Video

Updated: Aug 11, 2026

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

The emerging functions of UCP2 in health, disease, and therapeutics

Gustav Mattiasson1, Patrick G Sullivan

  • 1Laboratory for Experimental Brain Research, Wallenberg Neuroscience Center, Lund, Sweden. Gustav.Mattiasson@med.lu.se

Antioxidants & Redox Signaling
|February 21, 2006
PubMed

Insights

Uncoupling protein 2 (UCP2) plays a key role in regulating reactive oxygen species, inflammation, and cell death. Its therapeutic potential varies by disease, requiring tissue-specific regulation for optimal outcomes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Uncoupling proteins (UCPs) are gaining attention as therapeutic targets for various diseases.
  • UCP2's specific physiological roles and therapeutic applications remain under investigation.
  • Unlike UCP1, UCP2 is not primarily involved in thermogenesis or weight control.

Purpose of the Study:

  • To explore the physiological functions of UCP2.
  • To investigate the therapeutic potential of UCP2 in disease models.
  • To understand the complex role of UCP2 in different pathological conditions.

Main Methods:

  • Review of existing literature on UCP2 function and disease association.
  • Analysis of experimental evidence from disease models.
  • Comparative analysis of UCP2's role in different tissues and diseases.

Main Results:

  • UCP2 regulates reactive oxygen species production, inflammation, and cell death.
  • Increased UCP2 expression/activity shows benefits in neurodegenerative and cardiovascular disease models.
  • UCP2 inhibits insulin secretion in type 2 diabetes but appears beneficial in associated cardiovascular risks.

Conclusions:

  • UCP2 has a multifaceted role in disease pathogenesis and progression.
  • Therapeutic strategies targeting UCP2 require careful consideration of tissue-specific effects.
  • UCP2 modulation holds promise for treating conditions like neurodegenerative diseases, cardiovascular diseases, and type 2 diabetes.

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...